What is the appropriate dose of Clexane (enoxaparin) for a patient with suspected Pulmonary Embolism (PE) who weighs 93 kg and is 153 cm tall?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a patient weighing 93 kg with a height of 153 cm who has a suspected pulmonary embolism (PE), I recommend administering enoxaparin (Clexane) at a dose of 1 mg/kg twice daily, which equals 93 mg (9,300 units) subcutaneously every 12 hours. This therapeutic dosing is appropriate while awaiting definitive diagnosis and potential transition to oral anticoagulation. The dose should be administered by subcutaneous injection in the abdominal wall, preferably at the same times each day. Before starting treatment, baseline coagulation studies and a complete blood count should be obtained. Renal function should also be assessed, as dose adjustment may be necessary if creatinine clearance is below 30 ml/min, as suggested by 1 and 1. Enoxaparin works by binding to antithrombin and enhancing its inhibition of coagulation factors, particularly factor Xa, thereby preventing clot extension and formation of new clots. Treatment should continue until the diagnosis is confirmed and a decision about longer-term anticoagulation is made, typically with transition to an oral anticoagulant if PE is confirmed. It's worth noting that the most recent guidelines, such as those from 1 and 1, support the use of enoxaparin in this context, with specific considerations for patients with renal insufficiency or obesity. However, the specific dosing recommendations provided in these guidelines align with the initial recommendation for a patient of this weight and condition. Thus, the chosen dose is consistent with current clinical practice guidelines and evidence-based medicine, as indicated by 1.

From the Research

Dosage of Clexane for Suspected PE

To determine the dosage of Clexane (enoxaparin) for a patient with suspected pulmonary embolism (PE), we need to consider the patient's weight.

  • The patient's weight is 93 kg.
  • The standard dosage of enoxaparin for PE is 1 mg/kg twice daily for 14 days during the acute phase, followed by 1.0 mg/kg or 1.5 mg/kg once daily during the chronic phase 2.
  • Based on this, the patient's dosage would be:
    • 93 kg x 1 mg/kg = 93 mg twice daily for the first 14 days.
    • After 14 days, the dosage could be adjusted to 93 mg once daily.

Considerations for Treatment

It's essential to note that the treatment of PE should be individualized, and the dosage of enoxaparin may need to be adjusted based on the patient's clinical response and risk factors.

  • The patient's height and weight should be considered when determining the dosage, as well as any potential renal impairment or other comorbidities.
  • Other anticoagulants, such as direct oral anticoagulants (DOACs), may also be considered for the treatment of PE, depending on the patient's specific needs and risk factors 3, 4, 5.

Comparison with Other Anticoagulants

  • Enoxaparin has been compared to other anticoagulants, such as dalteparin, in terms of effectiveness for VTE prophylaxis 6.
  • The choice of anticoagulant should be based on the patient's individual needs and risk factors, as well as the specific clinical scenario.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Update on pharmacologic therapy for pulmonary embolism.

Journal of cardiovascular pharmacology and therapeutics, 2014

Research

Real-world comparative effectiveness of dalteparin and enoxaparin for venous thromboembolism prophylaxis.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.